Positive Federal Legislation Could Lead to Exponential Growth in Marijuana and CBD Industry - Seite 2

An initial production run of Half-Baked™ cannabis infused cookies is expected to be completed shortly, and product should be on shelf during the month of May 2018.  

Kush Bottles, Inc. (OTCQB: KSHB)

Market Cap: $362,664,878, current share price: $5.65 

Kush Bottles, Inc. a leading provider of packaging, supplies, vaporizers, accessories and branding solutions for the regulated cannabis industry, announced yesterday that it has partnered with MainStem, a technology-based ancillary product distribution company for the regulated cannabis industry, to be the inaugural partner for MainStem's Vendor Program (MVP).  The company's security is up considerably this year, and back in February hit a 52 week high of $8.51.  

AbbVie, Inc. (NYSE: ABBV)

Market Cap: $161.9B, current share price: $102.07 

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Their Marinol drug is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC and is delivered as an oral capsule.

ABBV recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.

Cara Therapeutics, Inc.  

Market Cap: $423.46M, current share price: $12.92 

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focusing on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic and inflammatory pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is currently in preclinical development.